Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons
- 5 April 2023
- journal article
- research article
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 56 (3) , 543-556
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 PatientsPLOS ONE, 2013
- Treatment of Vestibular Schwannoma Cells With ErbB InhibitorsOtology & Neurotology, 2012
- Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2Neuro-Oncology, 2011
- Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 PatientsOtology & Neurotology, 2010
- Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related TumorsCancer Research, 2010
- Birth incidence and prevalence of tumor‐prone syndromes: Estimates from a UK family genetic register serviceAmerican Journal of Medical Genetics Part A, 2010
- Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II StudyJournal of Clinical Oncology, 2009
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2New England Journal of Medicine, 2009
- Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2Nature, 1993
- A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressorCell, 1993